XANTHINE OXIDASE INHIBITORY PROPERTIES OF 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES
Abstract
Xanthine oxidase (XO) is a versatile metalloflavoprotein enzyme that is best known for its rate-limiting role in the purine degradation pathway. Therapeutic inhibition of XO is based on its role in a variety of diseases that is attributed either to the hyperproduction of uric acid, or the hyperproduction of reactive oxygen species. Herein, we report an assessment of XO inhibitory properties of 24 1,2,3,4-tetrahydroisoquinoline derivatives, among which compound 16 exhibited IC50 value of 135.72 ± 2.71 µM. The interaction of compound 16 with XO enzyme was simulated using the Site Finder module, molecular docking and molecular dynamics. Molecular modeling suggests that interactions with Met 1038, Gln 1040, Thr 1077, Gln 1194 and Val 1259 are an important factor for inhibitor affinity toward the XO enzyme. Our proposed binding model might be beneficial for the discovery of new active 1,2,3,4-tetrahydroisoquinoline-based inhibitors of XO enzyme.
References
Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555 (3):589-606. [CrossRef][PubMed]
Cao W, Fang Y, Wu T, Liang F, Cheng Y, Salah M, et al. Insights from multispectral and molecular docking investigation on the xanthine oxidase inhibition by 1,4-dicaffeoylquinic acid. J Mol Struct 2020:128475. [CrossRef]
Desmond, Desmond Molecular Dynamics System (computer program). Version 2018.4. New York (NY): D.E. Shaw Research; 2018.
Džambaski Z, Bondžić BP. Dehydrogenative C(sp3)–H bond functionalization of tetrahydroisoquinolines me-diated by organic oxidants under mild conditions. Org Biomol Chem 2019;17(26):6420-5. [CrossRef][PubMed]
Li P, Tian Y, Zhai H, Deng F, Xie M, Zhang X. Study on the activity of non-purine xanthine oxidase inhibitor by 3D-QSAR modeling and molecular docking. J Mol Struct 2013;1051:56-65. [CrossRef]
Liu K, Kokubo H. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: a cross-docking study. J Chem Inf Model 2017;57(10):2514-22. [CrossRef][PubMed]
Malik N, Dhiman P, Khatkar A. Mechanistic approach towards interaction of newly synthesized hesperidin derivatives against xanthine oxidase. Int J Biol Macromol 2019;135:864-76. [CrossRef][PubMed]
MOE, Molecular Operating Environment (computer program). Version 2019.0101. Montreal (Canada): Chemical Computing Group ULC; 2019.
Ojha R, Singh J, Ojha A, Singh H, Sharma S, Nepali K. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat 2017;27(3):311-45. [CrossRef][PubMed]
Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidore-ductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 2004;101(21):7931-6. [CrossRef][PubMed]
Pacher PA, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58(1):87-114. [CrossRef][PubMed]
Pauff JM, Cao H, Hille R. Substrate orientation and catalysis at the molybdenum site in xanthine oxidase crystal structures in complex with xanthine and lumazine. J Biol Chem 2009;284(13):8760-7. [CrossRef][PubMed]
Šmelcerović A, Tomović K, Šmelcerović Ž, Petronijević Ž, Kocić G, Tomašič T, et al. Xanthine oxidase inhi-bitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem 2017;135:491-516. [CrossRef][PubMed]
Šmelcerovic Ž, Veljković A, Kocić G, Yancheva D, Petronijević Ž, Anderluh M, Šmelcerović A. Xanthine oxidase inhibitory properties and anti-inflammatory activity of 2-amino-5-alkylidene-thiazol-4-ones. Chem Biol Interact 2015;229:73-81. [CrossRef][PubMed]
Soga S, Shirai H, Kobori M, Hirayama N. Use of amino acid composition to predict ligand-binding sites. J Chem Inf Model 2007;47(2):400-6. [CrossRef][PubMed]
Tomović K, Ilić BS, Šmelcerović Ž, Miljković M, Yancheva D, Kojić M, Mavrova AT, Kocić G, Šmelcerović A. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors. Chem Biol Interact 2020;315:108873. [CrossRef][PubMed]
Wan Y, Zou B, Zeng H, Zhang L, Chen M, Fu G. Inhibitory effect of verbascoside on xanthine oxidase activity. Int J Biol Macromol 2016;93:609-14. [CrossRef][PubMed]